PUBLISHER: IMARC | PRODUCT CODE: 1753889
PUBLISHER: IMARC | PRODUCT CODE: 1753889
The global genotyping market size reached USD 21.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 63.3 Billion by 2033, exhibiting a growth rate (CAGR) of 11.90% during 2025-2033.
Genotyping refers to an analytical procedure that examines DNA sequences to determine the genetic constitution in the genotypes of living organisms, including humans, plants, animals, and microorganisms. Genetic tests enable scientists to examine a variety of genetic deviations, such as changes in DNA structure and single nucleotide polymorphisms, by detecting genetic differences through biological assays. By using this information, the differences between individuals can be compared while providing data related to the genetic history of an individual. Genotyping of microorganisms, such as viruses and bacteria, on the other hand, helps prevent the spread of pathogens by pinpointing the source of viral and bacterial diseases.
The global market is majorly driven by the rising demand for genotypic-based diagnostic testing in healthcare facilities across the globe. This can be attributed to the increasing prevalence of chronic diseases, including cancer and genetic disorders. In addition to this, the rising adoption of bioinformatics solutions in data analysis and pharmacogenomics in the drug discovery and development processes is also providing an impetus to the market growth. The market is further driven by the substantial rise in investments in research and development (R&D) activities focusing on genomic drug development and precision medicine research. Apart from this, the escalating demand for reagents for the augmenting volumes of genotyping tests on the global level is creating a positive outlook for the market. Some of the other factors that are contributing to the growth of the market include the rising geriatric population that is susceptible to developing numerous medical conditions, continual technological advancements in genotyping products, the growing awareness regarding personalized medicines among the masses and a considerable expansion of healthcare expenditure.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Qiagen N.V, Standard BioTools Inc. and Thermo Fisher Scientific Inc.